Live Breaking News & Updates on Day one biopharmaceuticals daily

Stay updated with breaking news from Day one biopharmaceuticals daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Parkman Healthcare Partners LLC Has $9.14 Million Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Parkman Healthcare Partners LLC raised its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 34.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 625,749 shares of the company’s stock after purchasing an additional 159,341 shares during the period. Day One Biopharmaceuticals […] ....

Arizona , United-states , Jeremy-bender , Piper-sandler , Principal-financial-group-inc , Goldman-sachs-group , Day-one-biopharmaceuticals-inc , Nasdaq , Quest-partners , Alps-advisors-inc , Jpmorgan-chase-co , Parkman-healthcare-partners

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Franklin Resources Inc.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Franklin Resources Inc.
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

China , Samuelc-blackman , Piper-sandler , Dynamic-technology-lab-private-ltd , Goldman-sachs-group , China-universal-asset-management-co , Exchange-commission , Securities-exchange-commission , Day-one-biopharmaceuticals-inc , Jpmorgan-chase-co , Franklin-resources-inc , Quest-partners

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Rating of "Moderate Buy" from Analysts

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 […] ....

China , Jeremy-bender , Piper-sandler , China-universal-asset-management-co , Day-one-biopharmaceuticals-inc , Needham-company , Jpmorgan-chase-co , Nasdaq , Quintet-private-bank-europe , Exchange-traded-concepts , Goldman-sachs-group , Quest-partners

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender Sells 7,873 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) CEO Jeremy Bender sold 7,873 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $16.08, for a total transaction of $126,597.84. Following the completion of the sale, the chief executive officer now […] ....

Timessquare , New-york , United-states , Piper-sandler , Jeremy-bender , York-mellon-corp , Vanguard-group-inc , Goldman-sachs-group , York-state-common-retirement-fund , Timessquare-capital-management , Needham-company , Nasdaq

FY2027 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Lowered by Analyst

FY2027 EPS Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Lowered by Analyst
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

China , Piper-sandler , Jeremy-bender , Jpmorgan-chase-co , Nasdaq , Quintet-private-bank-europe , Exchange-traded-concepts , Needham-company , Day-one-biopharmaceuticals-inc , Goldman-sachs-group , Quest-partners , Day-one-biopharmaceuticals-company-profile